|
1
|
Shen L, Shan YS, Hu HM, Price TJ, Sirohi
B, Yeh KH, Yang YH, Sano T, Yang HK, Zhang X, et al: Management of
gastric cancer in Asia: Resource-stratified guidelines. Lancet
Oncol. 14:e535–e547. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Henning GT, Schild SE, Stafford SL,
Donohue JH, Burch PA, Haddock MG and Gunderson LL: Results of
irradiation or chemoirradiation for primary unresectable, locally
recurrent, or grossly incomplete resection of gastric
adenocarcinoma. Int J Radiat Oncol Biol Phys. 46:109–118. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Jansen EP, Boot H, Verheij M and van de
Velde CJ: Optimal locoregional treatment in gastric cancer. J Clin
Oncol. 23:4509–4517. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Smalley SR, Gunderson L, Tepper J,
Martenson JA Jr, Minsky B, Willett C and Rich T: Gastric surgical
adjuvant radiotherapy consensus report: Rationale and treatment
implementation. Int J Radiat Oncol Biol Phys. 52:283–293. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Salomon DS, Brandt R, Ciardiello F and
Normanno N: Epidermal growth factor-related peptides and their
receptors in human malignancies. Crit Rev Oncol Hematol.
19:183–232. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kim MA, Lee HS, Lee HE, Jeon YK, Yang HK
and Kim WH: EGFR in gastric carcinomas: Prognostic significance of
protein overexpression and high gene copy number. Histopathology.
52:738–746. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Herbst RS: Review of epidermal growth
factor receptor biology. Int J Radiat Oncol Biol Phys. 59 Suppl
2:S21–S26. 2004. View Article : Google Scholar
|
|
9
|
Baumann M and Krause M: Targeting the
epidermal growth factor receptor in radiotherapy: Radiobiological
mechanisms, preclinical and clinical results. Radiother Oncol.
72:257–266. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Chinnaiyan P, Huang S, Vallabhaneni G,
Armstrong E, Varambally S, Tomlins SA, Chinnaiyan AM and Harari PM:
Mechanisms of enhanced radiation response following epidermal
growth factor receptor signaling inhibition by erlotinib (Tarceva).
Cancer Res. 65:3328–3335. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Bonner JA, Harari PM, Giralt J, Azarnia N,
Shin DM, Cohen RB, Jones CU, Sur R, Raben D, Jassem J, et al:
Radiotherapy plus cetuximab for squamous-cell carcinoma of the head
and neck. N Engl J Med. 354:567–578. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Harari P and Huang S: Radiation combined
with EGFR signal inhibitors: Head and Neck cancer focus. Semin
Radiat Oncol. 16:38–44. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lammering G: Molecular predictor and
promising target: Will EGFR now become a star in radiotherapy?
Radiother Oncol. 74:89–91. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yewale C, Baradia D, Vhora I, Patil S and
Misra A: Epidermal growth factor receptor targeting in cancer: A
review of trends and strategies. Biomaterials. 34:8690–8707. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Bell A, Wang ZJ, Arbabi-Ghahroudi M, Chang
TA, Durocher Y, Trojahn U, Baardsnes J, Jaramillo ML, Li S, Baral
TN, et al: Differential tumor-targeting abilities of three
single-domain antibody formats. Cancer Lett. 289:81–90. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sha H, Zou Z, Xin K, Bian X, Cai X, Lu W,
Chen J, Chen G, Huang L, Blair AM, et al: Tumor-penetrating peptide
fused EGFR single-domain antibody enhances cancer drug penetration
into 3D multicellular spheroids and facilitates effective gastric
cancer therapy. J Control Release. 200:188–200. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Balkwill FR and Mantovani A:
Cancer-related inflammation: Common themes and therapeutic
opportunities. Semin Cancer Biol. 22:1–40. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Huang SM, Li J, Armstrong EA and Harari
PM: Modulation of radiation response and tumor-induced angiogenesis
after epidermal growth factor receptor inhibition by ZD1839
(Iressa). Cancer Res. 62:4300–4306. 2002.PubMed/NCBI
|
|
19
|
Milas L, Mason K, Hunter N, Petersen S,
Yamakawa M, Ang K, Mendelsohn J and Fan Z: In vivo enhancement of
tumor radioresponse by C225 antiepidermal growth factor receptor
antibody. Clin Cancer Res. 6:701–708. 2000.PubMed/NCBI
|
|
20
|
Bianco C, Tortora G, Bianco R, Caputo R,
Veneziani BM, Caputo R, Damiano V, Troiani T, Fontanini G, Raben D,
et al: Enhancement of antitumor activity of ionizing radiation by
combined treatment with the selective epidermal growth factor
receptor-tyrosine kinase inhibitor ZD1839 (Iressa). Clin Cancer
Res. 8:3250–3258. 2002.PubMed/NCBI
|
|
21
|
Eriksen JG, Steiniche T and Overgaard J;
Danish Head and Neck Cancer study group (DAHANCA), : The influence
of epidermal growth factor receptor and tumor differentiation on
the response to accelerated radiotherapy of squamous cell
carcinomas of the head and neck in the randomized DAHANCA 6 and 7
study. Radiother Oncol. 74:93–100. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Bentzen SM, Atasoy BM, Daley FM, Dische S,
Richman PI, Saunders MI, Trott KR and Wilson GD: Epidermal growth
factor receptor expression in pretreatment biopsies from head and
neck squamous cell carcinoma as a predictive factor for a benefit
from accelerated radiation therapy in a randomized controlled
trial. J Clin Oncol. 23:5560–5567. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Mendelsohn J and Baselga J: Epidermal
growth factor receptor targeting in cancer. Semin Oncol.
33:369–385. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Schmidt-Ullrich RK, Mikkelsen RB, Dent P,
Todd DG, Valerie K, Kavanagh BD, Contessa JN, Rorrer WK and Chen
PB: Radiation-induced proliferation of the human A431 squamous
carcinoma cells is dependent on EGFR tyrosine phosphorylation.
Oncogene. 15:1191–1197. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Sturla LM, Amorino G, Alexander MS,
Mikkelsen RB, Valerie K and Schmidt-Ullrichr RK: Requirement of
Tyr-992 and Tyr-1173 in phosphorylation of the epidermal growth
factor receptor by ionizing radiation and modulation by SHP2. J
Biol Chem. 280:14597–14604. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Huang SM, Bock JM and Harari PM: Epidermal
growth factor receptor blockade with C225 modulates proliferation,
apoptosis, and radiosensitivity in squamous cell carcinomas of the
head and neck. Cancer Res. 59:1935–1940. 1999.PubMed/NCBI
|
|
27
|
Marmor MD, Skaria KB and Yarden Y: Signal
transduction and oncogenesis by ErbB/HER receptors. Int J Radiat
Oncol Biol Phys. 58:903–913. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ciardiello F and Tortora G: A novel
approach in the treatment of cancer: Targeting the epidermal growth
factor receptor. Clin Cancer Res. 7:2958–2970. 2001.PubMed/NCBI
|
|
29
|
Gibson MK, Abraham SC, Wu TT, Burtness B,
Heitmiller RF, Heath E and Forastiere A: Epidermal growth factor
receptor, p53 mutation, and pathological response predict survival
in patients with locally advanced esophageal cancer treated with
preoperative chemoradiotherapy. Clin Cancer Res. 9:6461–6468.
2003.PubMed/NCBI
|
|
30
|
Giralt J, de las Heras M, Cerezo L, Eraso
A, Hermosilla E, Velez D, Lujan J, Espin E, Rosello J, Majó J, et
al: The expression of epidermal growth factor receptor results in a
worse prognosis for patients with rectal cancer treated with
preoperative radiotherapy: A multicenter, retrospective analysis.
Radiother Oncol. 74:101–108. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Chakravarti A, Seiferheld W, Tu X, Wang H,
Zhang HZ, Ang KK, Hammond E, Curran W Jr and Mehta M:
Immunohistochemically determined total epidermal growth factor
receptor levels not of prognostic value in newly diagnosed
glioblastoma multiforme: Report from the radiation therapy oncology
group. Int J Radiat Oncol Biol Phys. 62:318–327. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Chakravarti A, Winter K, Wu CL, Kaufman D,
Hammond E, Parliament M, Tester W, Hagan M, Grignon D, Heney N, et
al: Expression of the epidermal growth factor receptor and Her-2
are predictors of favorable outcome and reduced complete response
rates, respectively, in patients with muscle-invading bladder
cancers treated by concurrent radiation and cisplatin-based
chemotherapy: A report from the Radiation Therapy Oncology Group.
Int J Radiat Oncol Biol Phys. 62:309–317. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Lee CM, Shrieve DC, Zempolich KA, Lee RJ,
Hammond E, Handrahan DL and Gaffney DK: Correlation between human
epidermal growth factor receptor family (EGFR, HER2, HER3, HER4),
phosphorylated Akt (P-Akt), and clinical outcomes after radiation
therapy in carcinoma of the cervix. Gynecol Oncol. 99:415–421.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Bonner JA, Maihle NJ, Folven BR,
Christianson TJ and Spain K: The interaction of epidermal growth
factor and radiation in human head and neck squamous cell carcinoma
cell lines with vastly different radiosensitivities. Int J Radiat
Oncol Biol Phys. 29:243–247. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Kwok TT and Sutherland RM: Enhancement of
sensitivity of human squamous carcinoma cells to radiation by
epidermal growth factor. J Natl Cancer Inst. 81:1020–1024. 1989.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zhu A, Shaeffer J, Leslie S, Kolm P and
El-Mahdi AM: Epidermal growth factor receptor: An independent
predictor of survival in astrocytic tumors given definitive
irradiation. Int J Radiat Oncol Biol Phys. 34:809–815. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Nyati MK, Morgan MA, Feng FY and Lawrence
TS: Integration of EGFR inhibitors with radiochemotherapy. Nat Rev
Cancer. 6:876–885. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Chen DJ and Nirodi CS: The epidermal
growth factor receptor: A role in repair of radiation-induced DNA
damage. Clin Cancer Res. 13:6555–6560. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Harari PM and Huang SM: Epidermal growth
factor receptor modulation of radiation response: Preclinical and
clinical development. Semin Radiat Oncol. 12 Suppl 2:S21–S26. 2002.
View Article : Google Scholar
|
|
40
|
Ahsan A, Hiniker SM, Davis MA, Lawrence TS
and Nyati MK: Role of cell cycle in epidermal growth factor
receptor Inhibitor-mediated radiosensitization. Cancer Res.
69:5108–5114. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Brown JM and Koong AC: High-dose
single-fraction radiotherapy: Exploiting a new biology? Int J
Radiat Oncol Biol Phys. 71:324–325. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Gerszten PC, Mendel E and Yamada Y:
Radiotherapy and radiosurgery for metastatic spine disease: What
are the options, indications, and outcomes? Spine (Phila Pa 1976).
34 Suppl 22:S78–S92. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Bradley JD, Paulus R, Komaki R, Masters G,
Blumenschein G, Schild S, Bogart J, Hu C, Forster K, Magliocco A,
et al: Standard-dose versus high-dose conformal radiotherapy with
concurrent and consolidation carboplatin plus paclitaxel with or
without cetuximab for patients with stage IIIA or IIIB
non-small-cell lung cancer (RTOG 0617): A randomised, two-by-two
factorial phase 3 study. Lancet Oncol. 16:187–199. 2015. View Article : Google Scholar : PubMed/NCBI
|
